US Patent 7993637 IL-11 muteins
Patent 7993637 was granted and assigned to CSL on August, 2011 by the United States Patent and Trademark Office.
All edits
Edits on 29 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 28 Nov, 2023
Golden AI
Edits made to:
Article (+283 characters)
Article
Patent abstract
The present invention relates generally to the treatment of an interleukin-11 (IL-11)-mediated condition. More particularly, the present invention provides the use of modified forms of IL-11 which modulate IL-11 signaling in the treatment of IL-11-mediated conditions.
Edits on 19 Sep, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Inventor Names
Manuel Baca0
Edits on 13 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07993637 IL-11 muteins US Patent 7993637 IL-11 muteins
Infobox
Patent Number
079936370
Patent Number
79936370
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
0
Patent Jurisdiction
Patent Number
079936370
Date of Patent
August 9, 2011
0Patent Application Number
122575650
Date Filed
October 24, 2008
0Patent Primary Examiner
Edits on 8 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07993637 IL-11 muteins
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07993637
Date of patent
August 9, 2011
Patent application number
12257565
Date Filed
October 24, 2008
Patent primary examiner
Find more entities like US Patent 7993637 IL-11 muteins
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.